Alopecia areata (AA) is a common autoimmune disease resulting from damage of the hair follicle by T cells. The immune pathways required for autoreactive T cell activation in AA are not defined limiting clinical development of rational targeted therapies1. Genome-wide association studies (GWAS)2 implicated ligands for the NKG2D receptor (product of the KLRK1 gene) in disease pathogenesis. Here, we show that cytotoxic CD8+NKG2D+ T cells are both necessary and sufficient for the induction of AA in mouse models of disease. Global transcriptional profiling of mouse and human AA skin revealed gene expression signatures indicative of cytotoxic T cell infiltration, an interferon-γ (IFN-γ) response and upregulation of several γ-chain (γc) cytokines known to promote the activation and survival of IFN-γ–producing CD8+NKG2D+ effector T cells. Therapeutically, antibody-mediated blockade of IFN-γ, interleukin-2 (IL-2) or interleukin-15 receptor β (IL-15Rβ) prevented disease development, reducing the accumulation of CD8+NKG2D+ T cells in the skin and the dermal IFN response in a mouse model of AA. Systemically administered pharmacological inhibitors of Janus kinase (JAK) family protein tyrosine kinases, downstream effectors of the IFN-γ and γc cytokine receptors, eliminated the IFN signature and prevented the development of AA, while topical administration promoted hair regrowth and reversed established disease. Notably, three patients treated with oral ruxolitinib, an inhibitor of JAK1 and JAK2, achieved near-complete hair regrowth within 5 months of treatment, suggesting the potential clinical utility of JAK inhibition in human AA.
At a glance
- Alopecia areata. N. Engl. J. Med. 366, 1515–1525 (2012). , &
- Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 466, 113–117 (2010). et al.
- Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J. Clin. Invest. 101, 62–67 (1998). , , , &
- Transfer of CD8+ cells induces localized hair loss whereas CD4+/CD25− cells promote systemic alopecia areata and CD4+/CD25+cells blockade disease onset in the C3H/HeJ mouse model. J. Invest. Dermatol. 124, 947–957 (2005). et al.
- Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J. Invest. Dermatol. 128, 1196–1206 (2008). et al.
- Alopecia areata in aging C3H/HeJ mice. J. Invest. Dermatol. 102, 847–856 (1994). , &
- Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J. Invest. Dermatol. 111, 797–803 (1998). , , &
- Abnormal interactions between perifollicular mast cells and CD8+ T cells may contribute to the pathogenesis of alopecia areata. PLoS ONE 9, e94260 (2014). et al.
- Transcriptional insights into the CD8+ T cell response to infection and memory T cell formation. Nat. Immunol. 14, 404–412 (2013). et al.
- Molecular definition of the identity and activation of natural killer cells. Nat. Immunol. 13, 1000–1009 (2012). et al.
- Interleukin-2 receptor α-chain expression in patients with alopecia areata. Acta Dermatovenerol. Croat. ADC 12, 154–156 (2004). , , &
- Interleukin 15: biology and relevance to human disease. Blood 97, 14–32 (2001). &
- Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes. Cell. Immunol. 174, 54–62 (1996). , &
- Reprogramming of CTLs into natural killer-like cells in celiac disease. J. Exp. Med. 203, 1343–1355 (2006). et al.
- Contribution of astrocyte-derived IL-15 to CD8 T cell effector functions in multiple sclerosis. J. Immunol. 185, 5693–5703 (2010). , , , &
- Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21, 357–366 (2004). et al.
- Interferon-γ-deficient mice are resistant to the development of alopecia areata. Br. J. Dermatol. 155, 515–521 (2006). et al.
- Alopecia areata induced in C3H/HeJ mice by interferon-γ: evidence for loss of immune privilege. J. Invest. Dermatol. 124, 288–289 (2005). , , &
- Reduced expression of interleukin-2 decreases the frequency of alopecia areata onset in C3H/HeJ mice. J. Invest. Dermatol. 125, 945–951 (2005). et al.
- Janus kinase inhibitors in autoimmune diseases. Ann. Rheum. Dis. 72 (suppl. 2), ii111–ii115 (2013). , , , &
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109–3117 (2010). et al.
- Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186, 4234–4243 (2011). et al.
- Gene Expression Dynamics Inspector (GEDI): for integrative analysis of expression profiles. Bioinformatics 19, 2321–2322 (2003). , &
- Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363, 1117–1127 (2010). et al.
- JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787–798 (2012). et al.
- Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J. Am. Acad. Dermatol. 67, 658–664 (2012). et al.
- A 'hairy' privilege. Trends Immunol. 26, 32–40 (2005). , &
- The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6, 595–601 (2006).
- Companies hope for kinase inhibitor JAKpot. Nat. Rev. Drug Discov. 10, 717–718 (2011).
- Supplementary Text and Figures (27,516 KB)
Supplementary Figures 1–17, Supplementary Tables 1–5 and Supplementary Methods